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To the Editor: Mulvey et al. (1) re-
ported the emergence of ciprofloxacin 
resistance in Salmonella enterica se-
rovar Kentucky of multilocus sequence 
type 198 (ST198) in Canada (1). Cip-
rofloxacin resistance in S. enterica ser. 
Kentucky was reported in 2011 in pa-
tients from Europe, most of whom had 
traveled to Africa and the Middle East 
(2). Since then, S. enterica ser. Ken-
tucky ST198 with additional resistance 
to third-generation cephalosporins and 
carbapenems has been reported from 
France and Morocco, again associ-
ated with travel (3). Poultry has been 
implicated as the most likely vehicle for 
infection by this sequence type (2,3). 
Resistance to third-generation cephalo-
sporins and carbapenems has not been 
seen in North America; however, the 
emergence of ciprofloxacin-resistant 
infections has been observed (1). 
In the United States, S. enterica 
ser. Kentucky is the most common se-
rotype isolated from chickens and the 
second most common found among 
retail chicken, but ciprofloxacin resis-
tance has not been documented among 
these sources (4). We sought to deter-
mine if ciprofloxacin- or ceftriaxone-
resistant S. enterica ser. Kentucky 
has emerged in humans in the United 
States. We examined isolates and data 
from the National Antimicrobial Re-
sistance Monitoring System to docu-
ment antimicrobial resistance and se-
quence type and to assess possible risk 
factors for acquiring infection.
Participating state and local 
public health laboratories submit 
every 20th nontyphoidal Salmo-
nella (NTS) isolate to the Centers 
for Disease Control and Prevention 
for susceptibility testing. MICs of 
>15 antimicrobial agents were deter-
mined by using broth microdilution 
(Sensititer, Cleveland, OH, USA) 
according to the manufacturer’s in-
structions. Where available, Clinical 
and Laboratory Standards Institute 
performance standards were used for 
interpretation of MICs; otherwise, 
interpretations established by the 
National Antimicrobial Resistance 
Monitoring System were used (5,6).
During 2009–2012, a total of 
21 (0.2%) of the 9,225 NTS isolates 
tested were S. enterica ser. Kentucky. 
Six (29%) were resistant to ciprofloxa-
cin; all were susceptible to ceftriaxone 
(Table) (5). As was observed in Cana-
da, the 6 resistant isolates were >80% 
similar by pulsed-field gel electropho-
resis analysis (XbaI; data not shown), 
and all 6 were ST198. Although a rare 
cause of human infection, S. enterica 
ser. Kentucky represented 23% (6/26) 
of all ciprofloxacin-resistant NTS de-
tected during 2009–2012. 
The median age of the 6 patients 
with ciprofloxacin-resistant S. enteri-
ca ser. Kentucky infections was 32 
years (range 9 months–56 years); 5 
(83%) were female. Of the 4 patients 
for whom information was available, 
2 were hospitalized, and 1 died. Spec-
imen sources were stool (n = 3) and 
urine (n = 3). Travel histories were 
obtained for 5 patients, and all had 
traveled internationally in the 7 days 
before specimen submission: 2 were 
residents of other countries (Saudi 
Arabia and Ethiopia), and 3 were 
US residents who had returned from 
travel to India. By comparison, only 
3 of 10 patients with ciprofloxacin-
susceptible infections had traveled 
(p = 0.02).
Resistance to ciprofloxacin in Sal-
monella is a growing concern because 
it limits treatment options for invasive 
disease. We describe ciprofloxacin-
resistant S. enterica ser. Kentucky 
isolated from 6 patients in the United 
States. The emerging global story of S. 
enterica ser. Kentucky ST198 demon-
strates the need for international inte-














type Antimicrobial resistance† 
AM41047 <1/F Black Ethiopia 2009 Stool AMP,	FIS,	GEN,	NAL,	STR,	TET 
AM45820 54/F Unknown Unknown 2010 Urine AMP,	COT,	FIS,	GEN,	NAL,	STR,	TET 
AM47052 56/F Asian India 2011 Urine AMP,	FIS,	GEN,	NAL,	STR,	TET 
2012AM-1081 2/F Asian India 2012 Stool AMP,	NAL 
AM50773 37/M Asian India 2012 Stool AMP,	AUG,	FIS,	GEN,	NAL,	STR,	TET 
2012AM-0353 42/F White Saudi	Arabia 2012 Urine AMP,	FIS,	FOX,	KAN,	NAL,	STR,	TET 
*ID,	identification;	AMP,	ampicillin;	AUG,	amoxicillin-clavulanic acid;	COT,	trimethoprim-sulfamethoxazole;	FIS,	sulfisoxazole;	FOX,	cefoxitin;	GEN,	
gentamicin;	KAN,	kanamycin;	NAL,	nalidixic	acid;	STR,	streptomycin;	TET,	tetracycline. 
†Resistance of isolate from infected patient to antimicrobial agents other than ciprofloxacin. 
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To the Editor: Crimean-Congo 
hemorrhagic fever (CCHF) is an acute 
viral infection that causes mild to se-
vere hemorrhagic fever characterized 
by petechiae, ecchymosis, dissemi-
nated intravascular coagulation, and 
multi-organ failure (1). The etiologic 
agent, CCHF virus (CCHFV; fam-
ily Bunyaviridae, genus Nairovirus), 
is maintained in enzootic cycles in-
volving agricultural and wild animals 
and the vector, Hyalomma ticks. (2). 
CCHF predominantly affects persons 
who have 1) substantial contact with 
ticks and/or agricultural animals in 
areas where CCHF is endemic or 2) 
close contact with infected persons, 
predominantly close relatives and 
health care workers. The case-fatality 
rate for CCHF is generally accepted as 
30% (1).
CCHF has a wide geographic 
distribution; cases have been reported 
in >30 countries across Africa, south-
eastern Europe, the Middle East, and 
western Asia. In the western African 
countries of Nigeria, Mauritania, and 
Senegal, serologic evidence of CCH-
FV infections in humans and agricul-
tural animals has been documented 
frequently (3–5); however, reports of 
the disease in humans have been limit-
ed to Senegal and Mauritania (6,7). In 
neighboring Mali, where the tick vec-
tor is known to be present, little infor-
mation exists regarding the presence 
of CCHFV. Thus, to determine if the 
virus is circulating undetected in Mali, 
we conducted a study to determine if 
CCHFV is present in Hyalomma ticks 
in the country.
In November 2011 and March 
2012, unfed Hyalomma ticks (adults 
and nymphs) were collected from 20 
cattle at the Daral livestock market 
(12° 49.855′ N, 08° 05.651′ W) near 
the town of Kati, Mali, ≈25 km from 
the capital, Bamako. In the field, ticks 
were visually identified to genus and 
pooled accordingly (3–4 ticks per 
pool, all collected from the same ani-
mal). A total of 23 tick pools, repre-
senting 80 ticks, were manually ho-
mogenized, and RNA was extracted 
and tested for the presence of CCHFV 
RNA by using in-house assays that 
selected for 3 virus genes. Of the 23 
tick pools tested, 1 was positive for 
CCHFV by all 3 assays. Phylogenetic 
analysis of the complete nucleocap-
sid protein gene (KF793333) showed 
that the CCHFV strain from Mali 
most closely resembled a strain from 
Mauritania (GenBank accession no. 
ArD39554), sharing 98% sequence 
identity (Figure, panel A). 
Further analysis of fragments of 
the medium segment (pre-Gn cod-
ing region, KF793334) and large 
segment (polymerase coding region, 
KF793335) confirmed these findings, 
showing sequence identities of 91% 
and 98%, respectively, with ArD39554 
(Figure, panels B, C). In a Biosafety 
Level 4 facility at Rocky Mountain 
Laboratories, Hamilton, Montana, 
USA, the original homogenates from 
the positive pool were passaged in 
multiple cell lines. After 3 passages, no 
discernible cytopathic effect was ob-
served and, aside from the initial pas-
sage, CCHFV RNA was not detected.
Genetic identification of ticks in 
the CCHFV RNA–positive pool was 
conducted as described (8,9). Ampli-
fied sequences most closely resem-
bled those of H. dromedarii, (97.2%–
100% sequence identity), although 
genetically, we cannot exclude the 
possibility that H. truncatum and H. 
rufipes were present with individual 
sequence identities of >97% to pub-
lished sequences.
The Daral cattle market in Kati 
is the largest of its kind in Mali, and 
animals from across the country come 
into the market every week. Although 
the market provided a convenient 
opportunity for collecting ticks, we 
cannot determine where the infected 
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	20,	No.	5,	May	2014	 911
